To the editor
Warfarin is a commonly used anticoagulant with a narrow therapeutic range and risk of hemorrhagic complications. [1] After CYP2C9 and VKORC1, CYP4F2 was confirmed as the third principle genetic determinant of warfarin dose variability. [2, 3] CYP4F2 functions as a vitamin K 1 (VK1) oxidase, a counterpart to vitamin K oxidize reductase (encoded by VKORC1) in limiting excessive accumulation of VK 1 in vitamin K cycle. [4] Genotypes of CYP2C9 and VKORC1 are associate with increased risk of over anticoagulation or bleeding events during warfarin therapy. [5] [6] [7] [8] [9] [10] However, little is known about the influence of CYP4F2. Herein we present the association of CYP4F2 polymorphism and risk of major hemorrhage in Chinese patients on warfarin. HapMap Data (Phase III/Rel#2, Feb09, on NCBI B36 assembly, dbSNP b126) covering 50 kb length centered on CYP4F2 for Chinese was downloaded (http://hapmap.ncbi. nlm.nih.gov/). Haplotype blocks were constructed using Haploview version 4.2 software. The tag SNPs were selected with an LOD score cutoff of 3.0 and r 2 threshold of 0.80. We genotyped eight tag SNPs (rs7251296, rs4808394, rs12610962, rs3093168, rs2074901, rs2018454, rs1558139 and rs3093200) in CYP4F2 using the multiplexed PCR-based SNaPshot system (Applied Biosystems) in 312 Han Chinese patients on warfarin. Three genetic determinants of warfarin dose, CYP2C9*3, VKORC1 -1639 G>A, and CYP4F2 V433M were also genotyped. Among the genotyped 312 patients (mean age, 56.6 ± 16.0 years; 50.6% men) on warfarin with the target international normalized ratio (INR) from 1.6 to 3.0, a total of 11 major and 69 minor hemorrhagic complications occurred over 147.25 person-years. The incidence for major hemorrhagic complications in this cohort (7.5 per 100 patients-years) was similar to those reported previously. [1, 6, 10] All participants were recruited consecutively from the Chinese PLA General Hospital. The protocol for this study was approved by the ethical review committee, and all subjects provided written informed consent. The association of the tag SNPs and the risk of major hemorrhagic complications (including serious, life-threatening and fatal bleeding episodes as defined by Fihn et al. [1] ) was evaluated using Cox proportional hazard regression with adjustment for potentially confounding variables.
Of all the tested CYP4F2 polymorphisms, only the SNP rs3093168 was statistically associated with major hemorrhagic complications. The incidence rate of major hemorrhagic complications was significantly higher among patients with CC alleles than those with the CG and GG alleles (17.1 vs. 4.5 per 100 patient-years), resulting in an adjusted hazard ratio (HR) of 7.61 (95%CI: 1.26-45.83) ( Table 1) . No other tag SNPs of CYP4F2 including V433M allele were statistically associated. All the major hemorrhagic complications in the patients with rs3093168 CC genotype occurred after the stabilization of warfarin anticoagulation.
The SNP rs3093168 located in intron 9 of CYP4F2 has never been studied. The genotype frequencies of CC in the Han Chinese (Beijing, China), Japanese (Tokyo, Japan), Caucasian (Utah, USA) and African (Ibadan, Nigeria) HapMap populations were 30%, 13%, 47% and 43%, respectively. Thus, a substantial portion of the populations harbor this genotype and might at higher risk for major hemorrhage when treated with warfarin. Validation of the association between CYP4F2 rs3093168 and major hemorrhage complications in larger ethnic diverse cohort, and functional analysis of the linked SNPs might confirm the contribution of CYP4F2 to the risk of haemorrhage complications in patients on warfarin. Hazard ratios were adjusted for age, sex, body surface area, initial and stable warfarin dose, target International Normalized Ratio, alcohol intake, number of comorbid conditions (including hypertension, hyperlipidemia, diabete mellitus, liver cirrhosis, stroke, nephritis, and malignant tumors), genotypes of CYP2C9*3 and VKORC1 -1639 G>A, and use of amiodarone.
